We tested the role of guaranteed delivery of medication in the prevention of relapse and the enhancement of adjustment in the community in patients with schizophrenia. Two hundred and ninety newly hospitalized patients at four hospitals were randomly assigned to groups receiving either long-acting ...
American biopharmaceutical research companies are currently developing almost 36 new medications for schizophrenia, and a total of 119 new medicines targeting
Current treatments for schizophrenia include medication and psychotherapy. Medications can be helpful, but they have a slew of uncomfortable side effects like weight gain, drowsiness, and more. These side effects can become so significant that people stop taking the medication, making schizophrenia ...
In contrast to most fields of medicine, progress to discover and develop new and improved psychiatric drugs has been slow and disappointing. The vast majority of currently prescribed drugs to treat schizophrenia, mood and anxiety disorders are arguably n
Alzheimer's disease (AD) is the leading cause of dementia, presenting a significant unmet medical need worldwide. The pathogenesis of AD involves various pathophysiological events, including the accumulation of amyloid and tau, neuro-inflammation, and ne
Auditory verbal hallucinations are one of the hallmarks of psychosis, particularly in people with schizophrenia, whichaffects 24 million people globally. These voices often bully or abuse the voice hearer, commenting incessantly on the person’s thoughts and behavior or even urging them t...
Clinical usefulness of amisulpride add-on therapy in schizophrenia patients without treatment response to second-generation antipsychotics. Clin Psychopharmacol Neurosci. 2021;19(1):117–24. Article CAS PubMed PubMed Central Google Scholar Zangani C, Giordano B, Stein HC, et al. Efficacy of ...
is designed to preferentially activate muscarinic receptor in the CNS and ameliorate the peripheral muscarinic side effects. It is reported that KarXT improves cognition in patients with AD and schizophrenia [67]. A 38-week phase 3 trial comparing the effects of KarXT (NCT05511363) and placebo in...
While these adverse effects are uncommon, they can be very serious; physicians must be vigilant for signs of pancreatitis and monitor kidney function among people taking GLP-1RA medications. Kidney problems can occur without symptoms until the condition is at an advanced stage with limited tre...
Weiden PJ, Olfson M: Cost of relapse in schizophrenia. Schizophr Bull. 1995, 21 (3): 419-429. 10.1093/schbul/21.3.419. Article CAS PubMed Google Scholar Lau DT, Nau DP: Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabe...